Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research
Collaborations aim to speed research and development approaches in Crohn’s disease and ulcerative colitisIcahn School of Medicine, Massachusetts General Hospital, The Scripps Research Institute...
CHEST: New Sub-Analyses Show Improvement in COPD Patient Outcomes with Spiolto® Respimat®
Studies show significant improvement with Spiolto® Respimat® in lung function across a range of age groups of patients* with COPD studied compared to tiotropium,...
AstraZeneca enters strategic immuno-oncology collaboration with Celgene Corporation to develop PD-L1 inhibitor programme for patients with serious blood cancers
AstraZeneca and MedImmune, the Company’s global biologics research and development arm, today announced that they have entered into an exclusive collaboration agreement with Celgene...
AstraZeneca to present further research into long-term prevention of cardiovascular events for patients with a history of heart attack at ESC Congress 2015
Over 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at this year’s European Society of Cardiology (ESC) Congress 2015...
US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved BRILINTA® (ticagrelor) tablets at a new 60mg dose to be used...
AstraZeneca enters license agreement with Daiichi Sankyo for development and commercialisation of FluMist in Japan
AstraZeneca today announced that its global biologics research and development arm, MedImmune, has entered an agreement granting Daiichi Sankyo Company, Ltd. (Daiichi Sankyo) an...
Immuno-oncology: an update on progress at the European Cancer Congress
Within the rapidly evolving world of cancer treatment and the excitement surrounding immuno-oncology, it is more important than ever to have a strategic approach...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...